SOURCE: AurimMed Pharma, Inc.

July 16, 2013 08:30 ET

AurimMed Pharma Receives Epilepsy Foundation's Inaugural Award

PARK CITY, UT--(Marketwired - Jul 16, 2013) - AurimMed Pharma, Inc., a biopharmaceutical company with an innovative approach to R&D and a unique Central Nervous System compound, has been named the first recipient of an award for the groundbreaking product for people with epilepsy from the Epilepsy Foundation. The Epilepsy Innovation Seal of Excellence was awarded by the Epilepsy Foundation of America in recognition of AurimMed's innovative principal lead drug candidate designated AMP-X-0079. (

"AurimMed has the highest respect for the Epilepsy Foundation and its leadership. We are pleased that they recognize our proprietary Privileged Structure Platform and our work towards the development of AMP-X-0079 for the treatment of epilepsy. This Award is an important and significant milestone in the evolution of AurimMed Pharma and the development of AMP-X-0079," said Amir Pesyan, Chairman and CEO of AurimMed.

"The AMP-X-0079 program has all the characteristics that we seek for the Epilepsy Innovation Seal of Excellence award," notes Roger J. Porter, MD, Chief Scientific Officer of the Epilepsy Foundation. "This potential drug has very impressive data from the NIH-NINDS screening program and has been created using a proven platform for success in other disease states."

Philip M. Gattone, President and CEO of the Epilepsy Foundation, further stated, "This award is based on the enthusiasm of the Epilepsy Foundation's Scientific Advisory Board and Business Advisory Board for the present accomplishments and future potential of AMP-X-0079 that we hope will alleviate the suffering of persons with epilepsy."

The Epilepsy Foundation has also presented AurimMed with a $25,000 award which has been earmarked for continued research. In considering AurimMed for this prestigious award, both the Foundation's Scientific and Business Advisory committees undertook a rigorous review of the AMP-X-0079 program and were enthusiastic for the following reasons: 1) The Privileged Structure Platform modifies and recombines features of clinically successful compounds as the starting point for the development of new compounds; this approach offers the potential for decreased toxicity and increased probability of successful regulatory drug product approval; 2) Although the program started with familiar chemical backbones, the resulting innovative compounds appear to have a new and novel mechanism of action; and 3) The lead compound, AMP-X-0079, has already demonstrated a very favorable profile in the NIH Anticonvulsant Screening Program.

About AurimMed Pharma, Inc:

AurimMed Pharma, Inc. is a private biopharmaceutical company based in Utah, with an innovative approach to R&D and a unique Central Nervous System (CNS) portfolio that leverages a safe, efficacious, and highly tolerable mode of action to treat several patient types. AurimMed is developing small-molecule pharmaceutical products by using carefully selected privileged structures as lead compounds for proprietary product development. The Company has developed 5 novel small-molecule lead compounds that treat both acute and chronic seizures in conditions such as epilepsy and chemically induced seizures, and may also be useful for chronic neuropathic pain, migraine prophylaxis, spinal muscular atrophy (SMA), Parkinson's disease, and other neurological disorders and neurodegenerative diseases.

For more information on AurimMed Pharma, Inc., email

About the Epilepsy Foundation:

The Epilepsy Foundation, a national non-profit with affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation's goals are to ensure that people with seizures are able to participate in all life experiences; and to prevent, control and cure epilepsy through services, education, advocacy and research, so not another moment is lost to seizures.

Safe Harbor Statement: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Statements in this release, which relate to the Company's plans and strategies, as well as management's expectations about new and existing products and services, acquisitions and opportunities, market growth, and demand for acceptance of new and existing products and services, are forward-looking statements. In particular, when used in the preceding discussion, the words "estimated," "believe," "optimistic," "expect," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to risks and uncertainties, and actual results could differ materially from those expressed in forward-looking statements. Such risks and uncertainties include, but are not limited to, unfavorable market conditions, increased competition, limited working capital, and failure to implement business strategies, actions by regulatory agencies, and other risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors. The Company undertakes no obligations to publicly update or revise such statements.

Contact Information